MUTATIONAL STATUS AND SOME CLINICO-MORPHOLOGICAL FEATURES OF CUTANEOUS MELANOMA


如何引用文章

全文:

详细

Cutaneous melanoma is characterized by molecular heterogeneity. The work is devoted to the analysis of mutational status of genes involved in MAPK signaling in primary and metastatic cutaneous melanoma for the detection of tumor sensitivity to the specific targeted therapy as well as possible links of genetic alterations in cutaneous melanoma with some clinical and morphological features. BRAF, NRAS and KIT mutations were found in 60.6%, 13.8% and 1% of cutaneous melanoma cases correspondingly. Mutational status of cutaneous melanoma is differed depending on tumor localization, chronic UV insolation and patients’ age. Thus the rate of the BRAF mutation in melanomas of trunk and extremities (64.7%) was higher than in melanomas of face and head (42.8%). The rate of BRAF mutation was shown to be not associated with pigmentation and tumor growth while NRAS mutation frequency in amelanotic melanoma was lower and in noddle melanoma - higher if compared with pigmented cutaneous melanoma in the radial growth phase. The trend in the association of mutations with melanoma histological type was shown for the first time, the highest rate of BRAF mutation was found in epithelioid melanoma. The obtained results are important for the treatment of cutaneous melanoma as mutational status determines the sensitivity of metastatic melanoma to specific targeted therapy in patients with BRAF, NRAS and KIT mutations.

作者简介

N. Mazurenko

N.N. Blokhin Russian Cancer Research Center

Email: nnmazurenko@mail.ru
д-р биол. наук, проф., заведующая лабораторией онкогеномики НИИ канцерогенеза. Moscow, 115478, Russian Federation

I. Tsyganova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

A. Lushnikova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

O. Anurova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

D. Ponkratova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

A. Vikhrova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

I. Utyashev

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

参考

  1. Мазуренко Н.Н. Молекулярно-генетические факторы и маркеры меланомы. В кн: Кушлинский Н.Е., Мазуренко Н.Н., Немцова М.В. (ред.) Молекулярно-генетические маркеры опухолей. М.: Издательство РАМН; 2016: 85-128.
  2. Rajkumar S., Watson I.R. Molecular characterization of cutaneous melanoma: creating a framework for targeted and immune therapies. Br. J. Cancer. 2016; 115(2): 145-55.
  3. Статистика злокачественных новообразований в России и странах СНГ в 2013 году / Под ред. М.И. Давыдова, Е.М. Аксель. М.; 2015: 217.
  4. Chakraborty R., Wieland C.N., Comfere N.I. Molecular targeted therapies in metastatic melanoma. Pharmacogen. Person. Med. 2013; 6: 49-56.
  5. Grimaldi A.M., Simeone E., Festino L. et al.Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Discovery Med. 2015; 19(107): 455-61.
  6. Bello D.M., Ariyan C.E., Carvajal R.D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013; 20(4): 261-81.
  7. Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol. 2008; 1(4): 395-405.
  8. Ellenrhorst J., Greene V.R., Ekmekcioglu S. Warneke C.L., Johnson M.M., Xoopr C.P. et al. Clinical correlations of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 2011; 17(2): 229-35.
  9. Tschandi P., Berghoff A.S., Preusser M., Burgstaller-Muehlbacher S., Pehamberger H., Okamoto I. et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One. 2013; 8(7): e69639.
  10. Ascierto P.A., McArthur G.A., Dréno B., Atkinson V., Liszkay G., Di Giacomo A.M. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9): 1248-60. doi: 10.1016/S1470-2045(16)30122-X
  11. Vennepureddy A., Thumallapally N., Motilal Nehru V., Atallah J.P., Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J. Clin. Med. Res. 2016; 8(2): 63-75. doi: 10.14740/jocmr2424w
  12. Мазуренко Н.Н., Цыганова И.В., Лушникова А.А., Понкратова Д.А., Анурова О.А., Черемушкин Е.А. и др. Спектр мутаций онкогенов различается в подтипах меланомы кожи. Молекул. биол 2015; 59(6): 1022-9.
  13. Франк Г.А., Завалишина Л.Э., Кекеева Т.В., Алексахина С.Н., Гарифуллина Т.Р., Иванцов О.А. и др. Первое Всероссийское молекулярно-эпидемиологическое исследование меланомы: результаты анализа мутаций в гене BRAF. Арх. пат. 2014, (3): 65-72.
  14. Jakob J.A., Bassett R.L.Jr., Ng C.S., Curry J.L., Joseph R.W., Alvarado G.C. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118(16): 4014-23.
  15. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S. et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949-54.
  16. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M. et al. Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116(6): 855-67.
  17. Bowyer S.E., Rao A.D., Lyle M., Sandhu S., Long G.V., McArthur G.A. et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res. 2014; 24(5): 504-8.
  18. Ross A.L., Sanchez M.I., Grichnik J.M. Molecular nevogenesis. Dermatol. Res. Pract. 2011. 463184. doi: 10.1155/2011/463184.
  19. Fedorenko I.V., Gibney G.T., Keiran S.M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32(25): 3009-18.

版权所有 © Eco-Vector, 2017


 


##common.cookie##